Q5129 Injection, vegzelma, 10 milligrams
Also known as: Vegzelma injection, bevacizumab-baka
Injection of Vegzelma, bevacizumab-baka biosimilar per 10 milligrams, a vascular endothelial growth factor antagonist.
In Plain Language
anti-angiogenic cancer drug; tumor growth blocker
Clinical Context
Indicated for metastatic cancers of colon, rectum, lung, breast, ovary, and cervix.
RVU Information
CPT Q5129 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5129?
CPT Q5129 (Injection, vegzelma, 10 milligrams) is a Q Codes code. Injection of Vegzelma, bevacizumab-baka biosimilar per 10 milligrams, a vascular endothelial growth factor antagonist.
Is Q5129 covered by insurance?
Q5129 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Indicated for metastatic cancers of colon, rectum, lung, breast, ovary, and cervix.
When is CPT Q5129 used?
Indicated for metastatic cancers of colon, rectum, lung, breast, ovary, and cervix.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.